BR0316131A - Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncer - Google Patents
Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncerInfo
- Publication number
- BR0316131A BR0316131A BR0316131-5A BR0316131A BR0316131A BR 0316131 A BR0316131 A BR 0316131A BR 0316131 A BR0316131 A BR 0316131A BR 0316131 A BR0316131 A BR 0316131A
- Authority
- BR
- Brazil
- Prior art keywords
- peripheral neuropathies
- carnitine
- acetyl
- prevention
- treatment
- Prior art date
Links
- 208000033808 peripheral neuropathy Diseases 0.000 title abstract 6
- 208000027232 peripheral nervous system disease Diseases 0.000 title abstract 5
- 230000002265 prevention Effects 0.000 title abstract 3
- 230000001093 anti-cancer Effects 0.000 title 1
- 229960004203 carnitine Drugs 0.000 title 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 4
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 229940079156 Proteasome inhibitor Drugs 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 229940122803 Vinca alkaloid Drugs 0.000 abstract 1
- 229940045985 antineoplastic platinum compound Drugs 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- PSNOPSMXOBPNNV-VVCTWANISA-N cryptophycin 1 Chemical class C1=C(Cl)C(OC)=CC=C1C[C@@H]1C(=O)NC[C@@H](C)C(=O)O[C@@H](CC(C)C)C(=O)O[C@H]([C@H](C)[C@@H]2[C@H](O2)C=2C=CC=CC=2)C/C=C/C(=O)N1 PSNOPSMXOBPNNV-VVCTWANISA-N 0.000 abstract 1
- 229930013356 epothilone Natural products 0.000 abstract 1
- 150000003883 epothilone derivatives Chemical class 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 150000003058 platinum compounds Chemical class 0.000 abstract 1
- 239000003207 proteasome inhibitor Substances 0.000 abstract 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- -1 taxanes Chemical class 0.000 abstract 1
- 229960003433 thalidomide Drugs 0.000 abstract 1
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/221—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/292,823 US20030199535A1 (en) | 1998-07-30 | 2002-11-13 | Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent |
| PCT/IT2003/000656 WO2004043454A1 (en) | 2002-11-13 | 2003-10-23 | Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0316131A true BR0316131A (pt) | 2005-09-27 |
Family
ID=32312146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0316131-5A BR0316131A (pt) | 2002-11-13 | 2003-10-23 | Acetil-l-carnitina para a prevenção e/ou tratamento de neuropatias periféricas induzidas por agentes anti-câncer |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US20030199535A1 (https=) |
| EP (1) | EP1562577B1 (https=) |
| JP (1) | JP2006508958A (https=) |
| KR (1) | KR20050075012A (https=) |
| CN (1) | CN1708297A (https=) |
| AR (1) | AR041947A1 (https=) |
| AT (1) | ATE526958T1 (https=) |
| AU (2) | AU2003283807B2 (https=) |
| BR (1) | BR0316131A (https=) |
| CA (1) | CA2505937C (https=) |
| CY (1) | CY1112399T1 (https=) |
| DK (1) | DK1562577T3 (https=) |
| ES (1) | ES2374503T3 (https=) |
| MX (1) | MXPA05004752A (https=) |
| PL (1) | PL379244A1 (https=) |
| PT (1) | PT1562577E (https=) |
| SI (1) | SI1562577T1 (https=) |
| TW (1) | TWI362260B (https=) |
| WO (1) | WO2004043454A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003018767A2 (en) * | 2001-08-27 | 2003-03-06 | Advanced Cell Technology, Inc. | Trans-differentiation and re-differentiation of somatic cells and production of cells for cell therapies |
| US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| US6921769B2 (en) | 2002-08-23 | 2005-07-26 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
| EP2186811A1 (en) | 2002-08-23 | 2010-05-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
| ITMI20070817A1 (it) * | 2007-04-19 | 2008-10-20 | Farmacetika Ltd | Composizione farmaceutica comprendente l-carnitina ed un agente antagonista dei recettori adenosinici di membrana, loro derivati e/o sali farmaceuticamente accettabili, e uso degli stessi nella preparazione di farmaci con effetto non tossico di inibi |
| WO2008136374A1 (ja) * | 2007-04-26 | 2008-11-13 | Nippon Shinyaku Co., Ltd. | 抗癌剤投与に伴う末梢神経障害抑制用医薬組成物 |
| US8613962B2 (en) * | 2007-08-31 | 2013-12-24 | Kyushu University, National University Corporation | Prophylactic or alleviating agent for peripheral nerve disorder induced by anti-cancer agent |
| WO2009092892A2 (fr) * | 2007-10-30 | 2009-07-30 | Trophos | Nouvelle composition pour traiter les effets secondaires des traitements anticancereux |
| JP2012510498A (ja) * | 2008-12-01 | 2012-05-10 | シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニ | 新生物の処置のための化学療法剤との組み合わせにおけるアルカノイルｌ−カルニチンの使用 |
| CN102060722B (zh) * | 2009-05-01 | 2014-06-11 | 常州高新技术产业开发区三维工业技术研究所有限公司 | 一种含砷化合物及其制备方法和用途 |
| ITPZ20130005A1 (it) * | 2013-07-05 | 2015-01-06 | Teodosio Antonio Ferrara | Metabolismo energetico e omeostasi |
| JP7075937B2 (ja) | 2016-11-09 | 2022-05-26 | キアゲン サイエンシーズ， エルエルシー | Ｓｅｑｕｅｎｃｉｎｇ－Ｂｙ－Ｓｙｎｔｈｅｓｉｓ法におけるイメージング試薬としての光防護性混合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4713370A (en) * | 1972-11-06 | 1987-12-15 | Felice Stephen L De | Carnitine and its use in reducing cardiac toxicity and as a synergist with cytostats |
| IL74449A (en) * | 1984-03-01 | 1988-07-31 | Us Commerce | Tetrahalo-1,2-cyclohexane-diamino platinum complexes and anti-neoplastic compositions comprising them |
| IT1196564B (it) * | 1986-08-04 | 1988-11-16 | Sigma Tau Ind Farmaceuti | Impiego di acetil l-carnitina nel trattamento terapeutico delle neuropatie periferiche |
| CA2338638C (en) * | 1998-07-30 | 2009-03-17 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity |
-
2002
- 2002-11-13 US US10/292,823 patent/US20030199535A1/en not_active Abandoned
-
2003
- 2003-10-23 AT AT03775788T patent/ATE526958T1/de active
- 2003-10-23 WO PCT/IT2003/000656 patent/WO2004043454A1/en not_active Ceased
- 2003-10-23 ES ES03775788T patent/ES2374503T3/es not_active Expired - Lifetime
- 2003-10-23 PL PL379244A patent/PL379244A1/pl unknown
- 2003-10-23 KR KR1020057008678A patent/KR20050075012A/ko not_active Ceased
- 2003-10-23 MX MXPA05004752A patent/MXPA05004752A/es active IP Right Grant
- 2003-10-23 DK DK03775788.7T patent/DK1562577T3/da active
- 2003-10-23 BR BR0316131-5A patent/BR0316131A/pt not_active IP Right Cessation
- 2003-10-23 PT PT03775788T patent/PT1562577E/pt unknown
- 2003-10-23 CN CNA2003801022169A patent/CN1708297A/zh active Pending
- 2003-10-23 JP JP2004551161A patent/JP2006508958A/ja active Pending
- 2003-10-23 AU AU2003283807A patent/AU2003283807B2/en not_active Ceased
- 2003-10-23 CA CA2505937A patent/CA2505937C/en not_active Expired - Fee Related
- 2003-10-23 EP EP03775788A patent/EP1562577B1/en not_active Expired - Lifetime
- 2003-10-23 SI SI200332090T patent/SI1562577T1/sl unknown
- 2003-10-30 TW TW092130286A patent/TWI362260B/zh not_active IP Right Cessation
- 2003-11-12 AR ARP030104151A patent/AR041947A1/es not_active Application Discontinuation
-
2006
- 2006-04-13 US US11/402,961 patent/US20060183798A1/en not_active Abandoned
-
2009
- 2009-04-08 AU AU2009201384A patent/AU2009201384A1/en not_active Abandoned
-
2012
- 2012-01-03 CY CY20121100001T patent/CY1112399T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL379244A1 (pl) | 2006-08-07 |
| WO2004043454A1 (en) | 2004-05-27 |
| CA2505937C (en) | 2011-07-26 |
| DK1562577T3 (da) | 2012-01-23 |
| US20030199535A1 (en) | 2003-10-23 |
| AU2003283807A1 (en) | 2004-06-03 |
| PT1562577E (pt) | 2012-01-12 |
| EP1562577A1 (en) | 2005-08-17 |
| JP2006508958A (ja) | 2006-03-16 |
| AU2003283807B2 (en) | 2009-12-03 |
| MXPA05004752A (es) | 2005-08-02 |
| TWI362260B (en) | 2012-04-21 |
| CN1708297A (zh) | 2005-12-14 |
| SI1562577T1 (sl) | 2012-01-31 |
| TW200410683A (en) | 2004-07-01 |
| KR20050075012A (ko) | 2005-07-19 |
| EP1562577B1 (en) | 2011-10-05 |
| ES2374503T3 (es) | 2012-02-17 |
| ATE526958T1 (de) | 2011-10-15 |
| US20060183798A1 (en) | 2006-08-17 |
| CY1112399T1 (el) | 2015-12-09 |
| CA2505937A1 (en) | 2004-05-27 |
| AR041947A1 (es) | 2005-06-01 |
| AU2009201384A1 (en) | 2009-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Giovannitti Jr et al. | Pharmacology of local anesthetics used in oral surgery | |
| ES2395462T3 (es) | Inhibidores selectivos de la recaptación de norepinefrina-serotonina para el tratamiento del síndrome de fibromialgia, síndrome de fatiga crónica y dolor | |
| CY1111088T1 (el) | Θεραπευτικη φαρμακοτεχνικη μορφη για χορηγηση τολτεροδινης με ελεγχομενη απελευθερωση | |
| US20130236573A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
| CY1112399T1 (el) | Ακετυλ-l-καρνιτινη για την προληψη και/ή τη θεραπεια περιφερικων νευροπαθειων που προκαλουνται απο θαλιδομιδη | |
| BRPI0712976A2 (pt) | uso de 2-aminotetralinas substituÍdas para a fabricaÇço de um medicamento para a prevenÇço, alÍvio e/ou tratamento de vÁrios tipos de dor | |
| CU23468B7 (es) | Forma de dosificación de pramipexol en una dosis única diaria | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| JP2008542378A (ja) | 精神病性障害を管理する方法および組成物 | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| EA003142B1 (ru) | Лекарственное средство, обладающее антидепрессивным действием, его применение и способ лечения | |
| ES2952672T3 (es) | Tratamiento del dolor neuropático asociado a la neuropatía periférica inducida por la quimioterapia | |
| BRPI0411451A (pt) | formas de dosagens orais de memantina | |
| BRPI0405657A (pt) | Método para o tratamento de insuficiência cardìaca grave e medicamento para o mesmo | |
| KR970025615A (ko) | 암 전이 억제제 | |
| RU2008119454A (ru) | Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом | |
| JP4672257B2 (ja) | エポチロンを含む組成物およびカルチノイド症候群の治療のためのそれらの使用 | |
| BR112015012497B1 (pt) | Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial | |
| BRPI0415651A (pt) | métodos para tratar, prevenir, modificar e/ou administrar fibromialgia, e para reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de fibromialgia, e, composição farmacêutica | |
| KR890006227A (ko) | 페놀-함유 진해성 액체 조성물 | |
| BR112014004339A2 (pt) | suspensão oral | |
| BRPI0718318A2 (pt) | Processos para tratamento de distúrbios de perturbação de comportamento. | |
| ES2275619T3 (es) | Quetiapina para el tratamiento de discinesia en pacientes no psicoticos. | |
| BRPI0406212A (pt) | Administração transdérmica de monoésteres de (r)-3,3-difenilpropilamina | |
| BRPI0414719A (pt) | regimes terapêuticos para administrar combinações de fármacos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 3A ANUIDADE(S). |
|
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 11A E 12A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |